{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinomas%2C+Squamous+Cell&page=7", "query": { "condition": "Carcinomas, Squamous Cell", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 2290, "total_pages": 229, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinomas%2C+Squamous+Cell&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinomas%2C+Squamous+Cell&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T02:12:06.829Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003040", "title": "S9709, Laser Surgery Plus Radiation Therapy in Treating Patients With Early Stage Cancer of the Larynx", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "laser surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "1997-09", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2012-06-15", "last_synced_at": "2026-10-03T02:12:06.829Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003040" }, { "nct_id": "NCT02029690", "title": "Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pleural Mesothelioma Malignant Advanced", "Peritoneal Mesothelioma Malignant Advanced", "Non-squamous Non-small Cell Lung Carcinoma", "Uveal Melanoma", "Hepatocellular Carcinoma", "Glioma", "Sarcomatoid Carcinoma" ], "interventions": [ { "name": "ADI-PEG 20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Polaris Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2014-04-23", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2020-09-25", "last_synced_at": "2026-10-03T02:12:06.829Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02029690" }, { "nct_id": "NCT03234712", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-321", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2017-10-10", "completion_date": "2021-04-14", "has_results": false, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-10-03T02:12:06.829Z", "location_count": 14, "location_summary": "Springdale, Arkansas • Los Angeles, California • Sacramento, California + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03234712" }, { "nct_id": "NCT02646319", "title": "Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced Malignant Neoplasm", "Cervical Squamous Cell Carcinoma", "Endometrial Carcinoma", "Malignant Uterine Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Solid Neoplasm", "Stage III Bladder Cancer", "Stage III Prostate Cancer", "Stage III Renal Cell Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Cervical Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Cervical Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Ovarian Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Renal Cell Cancer", "Stage IVA Bladder Cancer", "Stage IVA Cervical Cancer", "Stage IVB Bladder Cancer", "Stage IVB Cervical Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nanoparticle Albumin-Bound Rapamycin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2016-01", "completion_date": "2018-04-24", "has_results": false, "last_update_posted_date": "2019-06-06", "last_synced_at": "2026-10-03T02:12:06.829Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02646319" }, { "nct_id": "NCT02432963", "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm", "Bladder Carcinoma", "Colon Carcinoma", "Estrogen Receptor Negative", "Head and Neck Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "HER2/Neu Negative", "Melanoma", "Non-Small Cell Lung Carcinoma", "Pancreatic Carcinoma", "Progesterone Receptor Negative", "Rectal Carcinoma", "Renal Cell Carcinoma", "Soft Tissue Sarcoma", "Triple-Negative Breast Carcinoma", "TP53 Gene Mutation", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Modified Vaccinia Virus Ankara Vaccine Expressing p53", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2016-06-14", "completion_date": "2026-10-02", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-10-03T02:12:06.829Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02432963" }, { "nct_id": "NCT07169734", "title": "A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Squamous Cell Carcinoma", "Squamous Non-small-cell Lung Cancer", "Colorectal Cancer", "Intrahepatic Cholangiocarcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "ALE.P03", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alentis Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2025-08-26", "completion_date": "2029-10-04", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-03T02:12:06.829Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT07169734" }, { "nct_id": "NCT05980000", "title": "Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Head and Neck Cancer", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Carcinoma", "Metastatic Head-and-neck Squamous-cell Carcinoma", "Metastatic Head and Neck Cancer", "HNSCC" ], "interventions": [ { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2023-10-27", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-10-03T02:12:06.829Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05980000" }, { "nct_id": "NCT02759900", "title": "Using a Cold Atmospheric Plasma Device to Treat Skin Disorders", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Actinic Keratosis", "Acne/Rosacea", "Verruca Plana", "Tinea", "Molluscum Contagiosum", "Bowen's Disease", "Warts" ], "interventions": [ { "name": "Non-thermal, atmospheric plasma to treat skin lesions and acne", "type": "DEVICE" }, { "name": "Indirect non-thermal, atmospheric plasma to treat hair loss and acne", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "The Skin Center Dermatology Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 100, "start_date": "2016-01", "completion_date": "2025-01", "has_results": false, "last_update_posted_date": "2022-04-12", "last_synced_at": "2026-10-03T02:12:06.829Z", "location_count": 1, "location_summary": "New City, New York", "locations": [ { "city": "New City", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02759900" }, { "nct_id": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Utomilumab", "type": "DRUG" }, { "name": "PF-04518600", "type": "DRUG" }, { "name": "PD 0360324", "type": "DRUG" }, { "name": "CMP-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 409, "start_date": "2015-11-09", "completion_date": "2023-03-23", "has_results": true, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-10-03T02:12:06.829Z", "location_count": 57, "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02554812" }, { "nct_id": "NCT03674567", "title": "Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "FLX475 (tivumecirnon)", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RAPT Therapeutics, Inc., a member of the GSK plc group of companies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 323, "start_date": "2018-09-25", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-03T02:12:06.829Z", "location_count": 19, "location_summary": "Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03674567" } ] }